Dow Jones Newswires
Sep 06, 2014
Gilead May be Pharma's No. 2 by Profit in 2015 -- Market Talk
11:34 EDT - Gilead (GILD) could be the world's second-biggest pharmaceutical company by net income in 2015 if Sovaldi sales keep growing, says Credit Suisse. It projects GILD's earnings to reach $15.1B next year, trailing just Johnson & Johnson's (JNJ) $18B, which of course sells much more than drugs. In 2013, GILD ranked 13th at $3.1B, says Credit Suisse. Sovaldi has had a record-setting launch the best launch of a new drug and is poised to help this year's GILD revenue more than double and EPS to quadruple.
MannKind (MNKD) Worth Watching:
The Zacks Consensus Estimate has also moved higher over the same period. This implies solid trading potential for the company. MannKind currently has a Zacks (Buy) ranking.
APPLE CEO " iPhone Sales Demand Is Staggering" LINK
Fly On the Wall
News Breaks October 23, 2014 AAPL Apple CEO says demand for new iPhone 'staggering'
Comment from Q4 earnings call.
Google also sells mobile ads. But it doesn't own a stream to sell ads against.
Meanwhile, Facebook keeps adding more streams to sell ads against
Time To buy Tesla ?
Reiterating overweight Rating on Tesla Motors stock and our 12 – 18 months price target of $385.
will be a strong Qt.
The Street Insider
Samsung Event Called 'Half Baked'; Cantor Reiterates Buy Rating on Apple (AAPL) Ahead of Fall Launch
September 4, 2014 9:02 AM EDT
Cantor Fitzgerald maintained a Buy rating on Apple (NASDAQ: AAPL) with a price target of $123.
GILD Abbie etc...
Published: November 15, 2014
By: Hannah Ishmael
Harvoni, Gilead‘s newer version of hepatitis C blockbuster Sovaldi, has received a strong reception since its launch this month, with prescription numbers already breaking Sovaldi‘s initial records
Gilead Sciences, Inc. (GILD), which led the hepatitis C virus (HCV) space last year with the launch of its blockbuster drug Sovaldi, is likely to continue the domination with its latest HCV drug Harvoni, which entered the market this month. Prescriptions for Harvoni are already breaking Sovaldi’s initial records.
The two drugs, along with Gilead’s premier HCV portfolio, are expected to continue bringing in record sales for the company. Citigroup Inc. has forecasted sales from Gilead’s HCV segment to reach $13 billion for the full-year 2014, compared to $9.33 billion last year
Nice uote From MD Anderson President
MD Anderson President Ron DePinho, M.D., said:
Genetically engineering our patients’ immune-system T cells to efficiently attack and destroy cancer cells represents one of the most exciting approaches with curative potential in oncology today. We believe coupling MD Anderson’s unique CAR T cell approach with the powerful technologies of ZIOPHARM and Intrexon will allow us to build T cells that hit cancer harder, with greater precision, under tighter control and with potentially fewer side effects for patients. This agreement ranks as one of MD Anderson’s most substantial collaborations and will provide significant resources to fuel its mission of Making Cancer History
Apple Pay makes a day at Walt Disney World even more seamless
Part of Tuesday's Apple announcement included a partnership with Walt Disney World, which will start using the new Apple Pay -- a mobile wallet system that allows customers to pay for purchases with a tap of their mobile device, eliminating the use of cards or bulky cash.
"Apple Pay makes shopping fast and easy for guests and simplifies the check-out process for our cast members," a Walt Disney Co. spokesperson told the Orlando Sentinel. "Our guests are going to love the convenience of Apple Pay, which will bring an easy, secure and private way to make purchases at Disney Store and Walt Disney World Resort.”
The Fly On The Wall
Breaking News Feed
Fierce Pharma ZIOP and XON CAR-T therapy is expected to be a game changer in the cancer immunotherapy landscape.
Apple Rising: iPhone 6 Pre-Orders Point to ‘Strong Demand